以国产阿霉素为主的化疗方案治疗恶性肿瘤62例的临床观察

Clinical observation of ADM containing chemotfaerapy in the treatment of malignant tumor

目的 评价以国产阿霉素为主的联合方案治疗恶性肿瘤的疗效及安全性。方法 62例经病理学确诊的恶性肿瘤患者,接受以国产阿霉素为主的联合化疗(ADM 40 mg/m2)。结果 完全缓解(CR)率为8％,部分缓解(PR)率为65％。总有效率达73％。主要不良反应为不同程度的骨髓抑制和脱发。结论 国产阿霉素(深圳万乐药业有限公司生产)在临床疗效和不良反应方面与进口阿霉素无明显差异,具有很好的有效性及安全性。

Objective To evaluate the efficacy and toxicity of ADM containing chemotherapy made in China, in the treatment of malignant tumor patients. Methods Sixty-two patients with biopsy-proven malignant diseases were treated by ADM containing chemotherapy at a dose of 40 mg/m2 with each patient receiving an average of 3.38 cycles(2-4 cycles). Results The over-all response rate(CR + PR)was 73% . Five of sixty-two patients achieved PR,and forty patients achieved CR.The main side effects were bone marrow suppression and alopecia. Conclusion The doxorubicin made by Shenzhen Main Luck Pharmaceuticals Inc. was proved useful in the efficacy and tolerability compared with the imported products.